How to Better Understand the New Currencies for Access

Expand your understanding of how ongoing funding is contingent on real-world clinical performance. Explore how RWE in lifecycle management involves navigating the shift toward HTA reassessments. You’ll walk away with practical tips to: 

• Understand how HTA agencies are thinking about generative AI 
• Analyze practical applications of generative AI across the RWE and market access lifecycle (e.g., evidence synthesis, protocol development, and supporting HTA and reimbursement planning) 
• Determine where AI can realistically add value today, as well as its current limitations 
• Develop governance, transparency, validation, and human oversight when using AI-generated outputs 
• Establish data quality and interoperability as foundational requirements for AI-enabled evidence generation 

Determine the strategic investments and multi-stakeholder partnerships required for you to transition from reactive data collection to a proactive, AI-enabled evidence strategy.